The global market for Endocannabinoid System Targeted Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Endocannabinoid System Targeted Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Endocannabinoid System Targeted Therapeutics by region & country, by Type, and by Application.

The Endocannabinoid System Targeted Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endocannabinoid System Targeted Therapeutics.

Market Segmentation

Scope of Endocannabinoid System Targeted Therapeutics - Market Report

Report Metric	Details
Report Name	Endocannabinoid System Targeted Therapeutics - Market
CAGR	5%
Segment by Type:	Oral Inhalation Others
Segment by Application	Autoimmune Disorders Genetic Disorders Neurological Disorders Pain Disorders
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GW Pharmaceuticals, MAKScientific, Corbus Pharmaceuticals, Tilray, Pure Green, Avicanna, GB Sciences, Botanix Pharmaceuticals, Therapix Biosciences, Zelira Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Endocannabinoid System Targeted Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Endocannabinoid System Targeted Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Endocannabinoid System Targeted Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Endocannabinoid System Targeted Therapeutics - Market report?

Ans: The main players in the Endocannabinoid System Targeted Therapeutics - Market are GW Pharmaceuticals, MAKScientific, Corbus Pharmaceuticals, Tilray, Pure Green, Avicanna, GB Sciences, Botanix Pharmaceuticals, Therapix Biosciences, Zelira Therapeutics

What are the Application segmentation covered in the Endocannabinoid System Targeted Therapeutics - Market report?

Ans: The Applications covered in the Endocannabinoid System Targeted Therapeutics - Market report are Autoimmune Disorders, Genetic Disorders, Neurological Disorders, Pain Disorders

What are the Type segmentation covered in the Endocannabinoid System Targeted Therapeutics - Market report?

Ans: The Types covered in the Endocannabinoid System Targeted Therapeutics - Market report are Oral, Inhalation, Others

1 Market Overview

1.1 Endocannabinoid System Targeted Therapeutics Product Introduction

1.2 Global Endocannabinoid System Targeted Therapeutics Market Size Forecast

1.3 Endocannabinoid System Targeted Therapeutics Market Trends & Drivers

1.3.1 Endocannabinoid System Targeted Therapeutics Industry Trends

1.3.2 Endocannabinoid System Targeted Therapeutics Market Drivers & Opportunity

1.3.3 Endocannabinoid System Targeted Therapeutics Market Challenges

1.3.4 Endocannabinoid System Targeted Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Endocannabinoid System Targeted Therapeutics Players Revenue Ranking (2023)

2.2 Global Endocannabinoid System Targeted Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Endocannabinoid System Targeted Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Endocannabinoid System Targeted Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Endocannabinoid System Targeted Therapeutics

2.6 Endocannabinoid System Targeted Therapeutics Market Competitive Analysis

2.6.1 Endocannabinoid System Targeted Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Endocannabinoid System Targeted Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endocannabinoid System Targeted Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Oral

3.1.2 Inhalation

3.1.3 Others

3.2 Global Endocannabinoid System Targeted Therapeutics Sales Value by Type

3.2.1 Global Endocannabinoid System Targeted Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Endocannabinoid System Targeted Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Endocannabinoid System Targeted Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Autoimmune Disorders

4.1.2 Genetic Disorders

4.1.3 Neurological Disorders

4.1.4 Pain Disorders

4.2 Global Endocannabinoid System Targeted Therapeutics Sales Value by Application

4.2.1 Global Endocannabinoid System Targeted Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Endocannabinoid System Targeted Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Endocannabinoid System Targeted Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Endocannabinoid System Targeted Therapeutics Sales Value by Region

5.1.1 Global Endocannabinoid System Targeted Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

5.2.2 North America Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

5.3.2 Europe Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

5.5.2 South America Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Endocannabinoid System Targeted Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Endocannabinoid System Targeted Therapeutics Sales Value

6.3 United States

6.3.1 United States Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.3.2 United States Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.4.2 Europe Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.5.2 China Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.6.2 Japan Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Endocannabinoid System Targeted Therapeutics Sales Value, 2019-2030

6.9.2 India Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Endocannabinoid System Targeted Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 GW Pharmaceuticals

7.1.1 GW Pharmaceuticals Profile

7.1.2 GW Pharmaceuticals Main Business

7.1.3 GW Pharmaceuticals Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.1.4 GW Pharmaceuticals Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 GW Pharmaceuticals Recent Developments

7.2 MAKScientific

7.2.1 MAKScientific Profile

7.2.2 MAKScientific Main Business

7.2.3 MAKScientific Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.2.4 MAKScientific Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 MAKScientific Recent Developments

7.3 Corbus Pharmaceuticals

7.3.1 Corbus Pharmaceuticals Profile

7.3.2 Corbus Pharmaceuticals Main Business

7.3.3 Corbus Pharmaceuticals Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.3.4 Corbus Pharmaceuticals Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 Tilray Recent Developments

7.4 Tilray

7.4.1 Tilray Profile

7.4.2 Tilray Main Business

7.4.3 Tilray Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.4.4 Tilray Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 Tilray Recent Developments

7.5 Pure Green

7.5.1 Pure Green Profile

7.5.2 Pure Green Main Business

7.5.3 Pure Green Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.5.4 Pure Green Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Pure Green Recent Developments

7.6 Avicanna

7.6.1 Avicanna Profile

7.6.2 Avicanna Main Business

7.6.3 Avicanna Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.6.4 Avicanna Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Avicanna Recent Developments

7.7 GB Sciences

7.7.1 GB Sciences Profile

7.7.2 GB Sciences Main Business

7.7.3 GB Sciences Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.7.4 GB Sciences Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 GB Sciences Recent Developments

7.8 Botanix Pharmaceuticals

7.8.1 Botanix Pharmaceuticals Profile

7.8.2 Botanix Pharmaceuticals Main Business

7.8.3 Botanix Pharmaceuticals Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.8.4 Botanix Pharmaceuticals Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.8.5 Botanix Pharmaceuticals Recent Developments

7.9 Therapix Biosciences

7.9.1 Therapix Biosciences Profile

7.9.2 Therapix Biosciences Main Business

7.9.3 Therapix Biosciences Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.9.4 Therapix Biosciences Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.9.5 Therapix Biosciences Recent Developments

7.10 Zelira Therapeutics

7.10.1 Zelira Therapeutics Profile

7.10.2 Zelira Therapeutics Main Business

7.10.3 Zelira Therapeutics Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

7.10.4 Zelira Therapeutics Endocannabinoid System Targeted Therapeutics Revenue (US$ Million) & (2019-2024)

7.10.5 Zelira Therapeutics Recent Developments

8 Industry Chain Analysis

8.1 Endocannabinoid System Targeted Therapeutics Industrial Chain

8.2 Endocannabinoid System Targeted Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Endocannabinoid System Targeted Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Endocannabinoid System Targeted Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

GW Pharmaceuticals

MAKScientific

Corbus Pharmaceuticals

Botanix Pharmaceuticals

Therapix Biosciences

Zelira Therapeutics

List of Tables

Table 1. Endocannabinoid System Targeted Therapeutics Market Trends

Table 2. Endocannabinoid System Targeted Therapeutics Market Drivers & Opportunity

Table 3. Endocannabinoid System Targeted Therapeutics Market Challenges

Table 4. Endocannabinoid System Targeted Therapeutics Market Restraints

Table 5. Global Endocannabinoid System Targeted Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Endocannabinoid System Targeted Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Endocannabinoid System Targeted Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Endocannabinoid System Targeted Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Endocannabinoid System Targeted Therapeutics

Table 10. Global Endocannabinoid System Targeted Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endocannabinoid System Targeted Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Endocannabinoid System Targeted Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Endocannabinoid System Targeted Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Endocannabinoid System Targeted Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Endocannabinoid System Targeted Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Endocannabinoid System Targeted Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Endocannabinoid System Targeted Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Endocannabinoid System Targeted Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Endocannabinoid System Targeted Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Endocannabinoid System Targeted Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Endocannabinoid System Targeted Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Endocannabinoid System Targeted Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Endocannabinoid System Targeted Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Endocannabinoid System Targeted Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Endocannabinoid System Targeted Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. GW Pharmaceuticals Basic Information List

Table 32. GW Pharmaceuticals Description and Business Overview

Table 33. GW Pharmaceuticals Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of GW Pharmaceuticals (2019-2024)

Table 35. GW Pharmaceuticals Recent Developments

Table 36. MAKScientific Basic Information List

Table 37. MAKScientific Description and Business Overview

Table 38. MAKScientific Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of MAKScientific (2019-2024)

Table 40. MAKScientific Recent Developments

Table 41. Corbus Pharmaceuticals Basic Information List

Table 42. Corbus Pharmaceuticals Description and Business Overview

Table 43. Corbus Pharmaceuticals Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Corbus Pharmaceuticals (2019-2024)

Table 45. Corbus Pharmaceuticals Recent Developments

Table 46. Tilray Basic Information List

Table 47. Tilray Description and Business Overview

Table 48. Tilray Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Tilray (2019-2024)

Table 50. Tilray Recent Developments

Table 51. Pure Green Basic Information List

Table 52. Pure Green Description and Business Overview

Table 53. Pure Green Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Pure Green (2019-2024)

Table 55. Pure Green Recent Developments

Table 56. Avicanna Basic Information List

Table 57. Avicanna Description and Business Overview

Table 58. Avicanna Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Avicanna (2019-2024)

Table 60. Avicanna Recent Developments

Table 61. GB Sciences Basic Information List

Table 62. GB Sciences Description and Business Overview

Table 63. GB Sciences Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of GB Sciences (2019-2024)

Table 65. GB Sciences Recent Developments

Table 66. Botanix Pharmaceuticals Basic Information List

Table 67. Botanix Pharmaceuticals Description and Business Overview

Table 68. Botanix Pharmaceuticals Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Botanix Pharmaceuticals (2019-2024)

Table 70. Botanix Pharmaceuticals Recent Developments

Table 71. Therapix Biosciences Basic Information List

Table 72. Therapix Biosciences Description and Business Overview

Table 73. Therapix Biosciences Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Therapix Biosciences (2019-2024)

Table 75. Therapix Biosciences Recent Developments

Table 76. Zelira Therapeutics Basic Information List

Table 77. Zelira Therapeutics Description and Business Overview

Table 78. Zelira Therapeutics Endocannabinoid System Targeted Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Endocannabinoid System Targeted Therapeutics Business of Zelira Therapeutics (2019-2024)

Table 80. Zelira Therapeutics Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Endocannabinoid System Targeted Therapeutics Downstream Customers

Table 84. Endocannabinoid System Targeted Therapeutics Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Endocannabinoid System Targeted Therapeutics Product Picture

Figure 2. Global Endocannabinoid System Targeted Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Endocannabinoid System Targeted Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Endocannabinoid System Targeted Therapeutics Report Years Considered

Figure 5. Global Endocannabinoid System Targeted Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Endocannabinoid System Targeted Therapeutics Revenue in 2023

Figure 7. Endocannabinoid System Targeted Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Oral Picture

Figure 9. Inhalation Picture

Figure 10. Others Picture

Figure 11. Global Endocannabinoid System Targeted Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Endocannabinoid System Targeted Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Autoimmune Disorders

Figure 14. Product Picture of Genetic Disorders

Figure 15. Product Picture of Neurological Disorders

Figure 16. Product Picture of Pain Disorders

Figure 17. Global Endocannabinoid System Targeted Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Endocannabinoid System Targeted Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Endocannabinoid System Targeted Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Endocannabinoid System Targeted Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Endocannabinoid System Targeted Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Endocannabinoid System Targeted Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Endocannabinoid System Targeted Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Endocannabinoid System Targeted Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Endocannabinoid System Targeted Therapeutics Sales Value (%), (2019-2030)

Figure 30. United States Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 36. China Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 38. China Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 48. India Endocannabinoid System Targeted Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Endocannabinoid System Targeted Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 50. India Endocannabinoid System Targeted Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 51. Endocannabinoid System Targeted Therapeutics Industrial Chain

Figure 52. Endocannabinoid System Targeted Therapeutics Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Fenoxaprop-p-ethyl Formulation Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-17P19155

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global General Medicines Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6U19155

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Plasma Medicine Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5K10490

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global No Additive Collection Tubes Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-4V10808

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions